S4: E6 Collaborating to Drive Global Progress in Clinical Research

Great.

So it's a good question.

And at a fundamental level, I think that partnerships have shifted from transactional execution models to really interdependent operating ecosystems.

10 years ago, responsibilities were more linear.

Sponsors designed, CROs executed, and the technology vendors supported.

And today, it's more linear.

And that's really the shift I've seen.

And then the globalization of development strategy has really changed the landscape.

It was always US, EU first, and then follow on everywhere else.

But now programs are increasingly designed to support simultaneous or near simultaneous development.

So we have to have that alignment upfront.

I totally agree.

I mean, I think as a technology partner, I mean, we don't necessarily just see ourselves as vendors in the global clinical trial ecosystem to Alicia's point.

So we really are very focused on being a tech partner.

And so I feel like you have a trifecta that's occurring where you have the sponsor, the CRO, and the tech partner that's part of that.

And to Alicia's point, you're sort of co-creating.

I think there are several things that are probably driving a lot of that, though.

You know, I think, first of all, the science is advancing like crazy and you're seeing more and more trials and cell and gene therapies, the rare diseases and precision oncology is also an area of focus that I know that we get pinged a lot about.

I think just the sheer amount of data that's being sort of ingested and utilized, I mean, which is hence the reasons for a lot of the platforms that we have.

And I think lastly, I mean, just thinking about the The sort of regulatory engagement and momentum that they're putting out there, whether they be sort of guidance documents or actual policy itself, that's really lending itself to much more innovation in this space.

And I think that it sort of creates a tremendous amount of excitement for all the parties involved.